SMS Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
SMS Pharmaceuticals has a total shareholder equity of ₹5.4B and total debt of ₹2.8B, which brings its debt-to-equity ratio to 52.4%. Its total assets and total liabilities are ₹10.3B and ₹5.0B respectively. SMS Pharmaceuticals's EBIT is ₹917.4M making its interest coverage ratio 4.2. It has cash and short-term investments of ₹362.0M.
Key information
52.4%
Debt to equity ratio
₹2.81b
Debt
| Interest coverage ratio | 4.2x |
| Cash | ₹362.03m |
| Equity | ₹5.36b |
| Total liabilities | ₹4.98b |
| Total assets | ₹10.34b |
Recent financial health updates
Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt Responsibly
Jun 21
SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Meaningful Debt Burden
Dec 09
Recent updates
SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Sep 07SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be Increased To ₹0.40
Aug 22Earnings Not Telling The Story For SMS Pharmaceuticals Limited (NSE:SMSPHARMA) After Shares Rise 27%
Aug 20SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Aug 08What SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 27% Share Price Gain Is Not Telling You
Jul 04Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt Responsibly
Jun 21SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 25% Share Price Surge Not Quite Adding Up
Feb 29SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be ₹0.30
Sep 11SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 28SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23SMS Pharmaceuticals (NSE:SMSPHARMA) Is Due To Pay A Dividend Of ₹0.30
Sep 15SMS Pharmaceuticals (NSE:SMSPHARMA) Will Pay A Dividend Of ₹0.30
Sep 01SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 18We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable Quality
Jun 03Should You Be Adding SMS Pharmaceuticals (NSE:SMSPHARMA) To Your Watchlist Today?
Mar 08What Type Of Shareholders Make Up SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Registry?
Feb 22The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 185% And Shareholders Are Boasting About It
Feb 08SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 18Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Meaningful Debt Burden
Dec 09Financial Position Analysis
Short Term Liabilities: SMSPHARMA's short term assets (₹5.3B) exceed its short term liabilities (₹3.3B).
Long Term Liabilities: SMSPHARMA's short term assets (₹5.3B) exceed its long term liabilities (₹1.7B).
Debt to Equity History and Analysis
Debt Level: SMSPHARMA's net debt to equity ratio (45.6%) is considered high.
Reducing Debt: SMSPHARMA's debt to equity ratio has increased from 42.4% to 52.4% over the past 5 years.
Debt Coverage: SMSPHARMA's debt is not well covered by operating cash flow (17.9%).
Interest Coverage: SMSPHARMA's interest payments on its debt are well covered by EBIT (4.2x coverage).